Diabetic cardiomyopathy and its mechanisms: Role of oxidative stress and damage

Journal of Diabetes Investigation

Volumn 5, Issue 6, 2014, Pages 623-634

  Liu, Quan ^a   Wang, Shudong ^a,b   Cai, Lu ^b  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b University of Louisville School of Medicine   (United States)

Author keywords

Anti oxidants; Diabetic cardiomyopathy; Oxidative stress

Indexed keywords

ADENYLATE KINASE; ADVANCED GLYCATION END PRODUCT; ANTIOXIDANT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CALCIUM ION; CURCUMIN; DIALLYL TRISULFIDE; FATTY ACID; METALLOTHIONEIN; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; RESVERATROL; SULFORAPHANE; TEMPOL; THIOREDOXIN 1; UBIDECARENONE;

APOPTOSIS; CALCIUM CELL LEVEL; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE DURATION; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION; HEART MUSCLE CELL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRX1 GENE; UPREGULATION;

EID: 84911428882     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12250     Document Type: Review

References (112)

1. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-1146.
2. Francis GS. Diabetic cardiomyopathy: fact or fiction? Heart 2001; 85: 247-248.
3. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 1053-1059.
4. Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602.
5. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
6. Koufen P, Ruck A, Brdiczka D, et al. Free radical-induced inactivation of creatine kinase: influence on the octameric and dimeric states of the mitochondrial enzyme (Mib-CK). Biochem J 1999; 344(Pt 2): 413-417.
7. Kowluru RA, Engerman RL, Kern TS. Diabetes-induced metabolic abnormalities in myocardium: effect of antioxidant therapy. Free Radic Res 2000; 32: 67-74.
8. Ustinova EE, Barrett CJ, Sun SY, et al. Oxidative stress impairs cardiac chemoreflexes in diabetic rats. Am J Physiol Heart Circ Physiol 2000; 279: H2176-H2187.
9. Uemura S, Matsushita H, Li W, et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001; 88: 1291-1298.
10. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004; 25: 543-567.
11. Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 2001; 1: 181-193.
12. Pang Y, Hunton DL, Bounelis P, et al. Hyperglycemia inhibits capacitative calcium entry and hypertrophy in neonatal cardiomyocytes. Diabetes 2002; 51: 3461-3467.
13. Ligeti L, Szenczi O, Prestia CM, et al. Altered calcium handling is an early sign of streptozotocin-induced diabetic cardiomyopathy. Int J Mol Med 2006; 17: 1035-1043.
14. Finck BN, Han X, Courtois M, et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 2003; 100: 1226-1231.
15. Diwan A, Tran T, Misra A, et al. Inflammatory mediators and the failing heart: a translational approach. Curr Mol Med 2003; 3: 161-182.
16. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625.
17. Bell DS. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 1995; 18: 708-714.
18. Rodrigues B, McNeill JH. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res 1992; 26: 913-922.
19. Spector KS. Diabetic cardiomyopathy. Clin Cardiol 1998; 21: 885-887.
20. Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. Prog Cardiovasc Dis 1985; 27: 255-270.
21. Solang L, Malmberg K, Ryden L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J 1999; 20: 789-795.
22. Bauters C, Lamblin N, Mc Fadden EP, et al. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol 2003; 2: 1.
23. Cai L, Kang YJ. Cell death and diabetic cardiomyopathy. Cardiovasc Toxicol 2003; 3: 219-228.
24. Li X, Xu Z, Li S, et al. Redox regulation of Ito remodeling in diabetic rat heart. Am J Physiol Heart Circ Physiol 2005; 288: H1417-H1424.
25. Retnakaran R, Zinman B. Type 1 diabetes, hyperglycaemia, and the heart. Lancet 2008; 371: 1790-1799.
26. Ginsberg BJ, Mazze R. Clinical consequences of the Diabetes Control and Complications Trial. N J Med 1994; 91: 221-224.
27. Wang J, Song Y, Wang Q, et al. Causes and characteristics of diabetic cardiomyopathy. Rev Diabet Stud 2006; 3: 108-117.
28. Willemsen S, Hartog JW, Hummel YM, et al. Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. Eur J Heart Fail 2011; 13: 76-82.
29. Way KJ, Isshiki K, Suzuma K, et al. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 2002; 51: 2709-2718.
30. Wakasaki H, Koya D, Schoen FJ, et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 1997; 94: 9320-9325.
31. Connelly KA, Kelly DJ, Zhang Y, et al. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail 2009; 2: 129-137.
32. Jweied EE, McKinney RD, Walker LA, et al. Depressed cardiac myofilament function in human diabetes mellitus. Am J Physiol Heart Circ Physiol 2005; 289: H2478-H2483.
33. Lim HS, MacFadyen RJ, Lip GY. Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. Arch Intern Med 2004; 164: 1737-1748.
34. Zhou G, Li X, Hein DW, et al. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J Am Coll Cardiol 2008; 52: 655-666.
35. Pacher P, Liaudet L, Soriano FG, et al. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 2002; 51: 514-521.
36. Chiu J, Farhangkhoee H, Xu BY, et al. PARP mediates structural alterations in diabetic cardiomyopathy. J Mol Cell Cardiol 2008; 45: 385-393.
37. Xu J, Zhou Q, Xu W, et al. Endoplasmic reticulum stress and diabetic cardiomyopathy. Exp Diabetes Res 2012; 2012: 827971.
38. Liu ZW, Zhu HT, Chen KL, et al. Protein kinase RNA-like endoplasmic reticulum kinase (PERK) signaling pathway plays a major role in reactive oxygen species (ROS)-mediated endoplasmic reticulum stress-induced apoptosis in diabetic cardiomyopathy. Cardiovasc Diabetol 2013; 12: 158.
39. Ji Y, Zhao Z, Cai T, et al. Liraglutide alleviates diabetic cardiomyopathy by blocking CHOP-triggered apoptosis via the inhibition of the IRE-alpha pathway. Mol Med Rep 2014; 9: 1254-1258.
40. Cai L, Li W, Wang G, et al. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 2002; 51: 1938-1948.
41. Cai L. Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy. Free Radic Biol Med 2006; 41: 851-861.
42. Ouyang C, You J, Xie Z. The interplay between autophagy and apoptosis in the diabetic heart. J Mol Cell Cardiol 2014; 71C: 71-80.
43. Mellor KM, Reichelt ME, Delbridge LM. Autophagy anomalies in the diabetic myocardium. Autophagy 2011; 7: 1263-1267.
44. Xie Z, He C, Zou MH. AMP-activated protein kinase modulates cardiac autophagy in diabetic cardiomyopathy. Autophagy 2011; 7: 1254-1255.
45. Russo SB, Baicu CF, Van Laer A, et al. Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J Clin Invest 2012; 122: 3919-3930.
46. Yang Z, Zingarelli B, Szabo C. Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. Shock 2000; 13: 60-66.
47. Szabo C. Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications. Pharmacol Res 2005; 52: 60-71.
48. Wold LE, Ren J. Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 map kinase-dependent oxidative stress mechanism. Biochem Biophys Res Commun 2004; 318: 1066-1071.
49. Boudina S, Sena S, O'Neill BT, et al. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 2005; 112: 2686-2695.
50. Steinberg HO, Paradisi G, Hook G, et al. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 2000; 49: 1231-1238.
51. Olukman M, Orhan CE, Celenk FG, et al. Apocynin restores endothelial dysfunction in streptozotocin diabetic rats through regulation of nitric oxide synthase and NADPH oxidase expressions. J Diabetes Complications 2010; 24: 415-423.
52. King MK, Coker ML, Goldberg A, et al. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res 2003; 92: 177-185.
53. Cesselli D, Jakoniuk I, Barlucchi L, et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 2001; 89: 279-286.
54. Takano H, Zou Y, Hasegawa H, et al. Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases. Antioxid Redox Signal 2003; 5: 789-794.
55. Samuel SM, Thirunavukkarasu M, Penumathsa SV, et al. Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation 2010; 121: 1244-1255.
56. Adluri RS, Thirunavukkarasu M, Zhan L, et al. Thioredoxin 1 enhances neovascularization and reduces ventricular remodeling during chronic myocardial infarction: a study using thioredoxin 1 transgenic mice. J Mol Cell Cardiol 2011; 50: 239-247.
57. Andreyev AY, Kushnareva YE, Starkov AA. Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc) 2005; 70: 200-214.
58. Nassar T, Kadery B, Lotan C, et al. Effects of the superoxide dismutase-mimetic compound tempol on endothelial dysfunction in streptozotocin-induced diabetic rats. Eur J Pharmacol 2002; 436: 111-118.
59. Jagadeesha DK, Lindley TE, Deleon J, et al. Tempol therapy attenuates medial smooth muscle cell apoptosis and neointima formation after balloon catheter injury in carotid artery of diabetic rats. Am J Physiol Heart Circ Physiol 2005; 289: H1047-H1053.
60. Gurusamy N, Watanabe K, Ma M, et al. Glycogen synthase kinase 3beta together with 14-3-3 protein regulates diabetic cardiomyopathy: effect of losartan and tempol. FEBS Lett 2006; 580: 1932-1940.
61. Taye A, Abouzied MM, Mohafez OM. Tempol ameliorates cardiac fibrosis in streptozotocin-induced diabetic rats: role of oxidative stress in diabetic cardiomyopathy. Naunyn Schmiedebergs Arch Pharmacol 2013; 386: 1071-1080.
62. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991; 57: 1-7.
63. Bengmark S. Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN J Parenter Enteral Nutr 2006; 30: 45-51.
64. Soetikno V, Sari FR, Sukumaran V, et al. Curcumin prevents diabetic cardiomyopathy in streptozotocin-induced diabetic rats: possible involvement of PKC-MAPK signaling pathway. Eur J Pharm Sci 2012; 47: 604-614.
65. Yu W, Wu J, Cai F, et al. Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats. PLoS ONE 2012; 7: e52013.
66. Wang Y, Zhou S, Sun W, et al. Inhibition of JNK by novel curcumin analog C66 prevents diabetic cardiomyopathy with a preservation of cardiac metallothionein expression. Am J Physiol Endocrinol Metab 2014; 306: e1239-1247.
67. Kolahdouz MR, Hosseinzadeh-Attar MJ, Eshraghian MR, et al. The effect of coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients. Minerva Gastroenterol Dietol 2013; 59: 231-236.
68. Carrasco J, Anglada FJ, Campos JP, et al. The protective role of coenzyme Q10 in renal injury associated with extracorporeal shockwave lithotripsy: a randomised, placebo-controlled clinical trial. BJU Int 2014; 113: 942-950.
69. Huynh K, Kiriazis H, Du XJ, et al. Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice. Free Radic Biol Med 2013; 60: 307-317.
70. Palsamy P, Subramanian S. Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Chem Biol Interact 2009; 179: 356-362.
71. Zhang H, Morgan B, Potter BJ, et al. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. Am J Physiol Heart Circ Physiol 2010; 299: H985-H994.
72. Thirunavukkarasu M, Penumathsa SV, Koneru S, et al. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 2007; 43: 720-729.
73. Sulaiman M, Matta MJ, Sunderesan NR, et al. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2010; 298: H833-H843.
74. Jian B, Yang S, Chaudry IH, et al. Resveratrol improves cardiac contractility following trauma-hemorrhage by modulating Sirt1. Mol Med 2012; 18: 209-214.
75. Cai L, Satoh M, Tohyama C, et al. Metallothionein in radiation exposure: its induction and protective role. Toxicology 1999; 132: 85-98.
76. Templeton DM, Cherian MG. Toxicological significance of metallothionein. Methods Enzymol 1991; 205: 11-24.
77. Davis SR, Cousins RJ. Metallothionein expression in animals: a physiological perspective on function. J Nutr 2000; 130: 1085-1088.
78. Vallee BL. The function of metallothionein. Neurochem Int 1995; 27: 23-33.
79. Bremner I, Beattie JH. Metallothionein and the trace minerals. Annu Rev Nutr 1990; 10: 63-83.
80. Cherian MG, Nordberg M. Cellular adaptation in metal toxicology and metallothionein. Toxicology 1983; 28: 1-15.
81. Chiaverini N, De Ley M. Protective effect of metallothionein on oxidative stress-induced DNA damage. Free Radic Res 2010; 44: 605-613.
82. Kang YJ. The antioxidant function of metallothionein in the heart. Proc Soc Exp Biol Med 1999; 222: 263-273.
83. Nath R, Kumar D, Li T, et al. Metallothioneins, oxidative stress and the cardiovascular system. Toxicology 2000; 155: 17-26.
84. Cai L, Kelein JB, Kang YJ. Metallothionein prevents diabetic cardiomyopathy. Toxicol Sci 2001; 60: 13.
85. Kang YJ, Cai L. Metallothionein suppression of diabetic cardiomyopathy by inhibition of hyperglycemia-induced oxidative stress. Free Radical Biol Med 2001; 31: 74.
86. Liang Q, Carlson EC, Donthi RV, et al. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 2002; 51: 174-181.
87. Cai L, Wang J, Li Y, et al. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes 2005; 54: 1829-1837.
88. Cai L, Wang Y, Zhou G, et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 48: 1688-1697.
89. Wold LE, Ceylan-Isik AF, Fang CX, et al. Metallothionein alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of Ca2+ cycling proteins, NADPH oxidase, poly(ADP-Ribose) polymerase and myosin heavy chain isozyme. Free Radic Biol Med 2006; 40: 1419-1429.
90. Velic A, Laturnus D, Chhoun J, et al. Diabetic basement membrane thickening does not occur in myocardial capillaries of transgenic mice when metallothionein is overexpressed in cardiac myocytes. Anat Rec (Hoboken) 2013; 296: 480-487.
91. Cai L. Metallothionein as an adaptive protein prevents diabetes and its toxicity. Nonlinearity Biol Toxicol Med. 2004; 2: 89-103.
92. Cai L. Diabetic cardiomyopathy and its prevention by metallothionein: experimental evidence, possible mechanisms and clinical implications. Curr Med Chem 2007; 14: 2193-2203.
93. Cong W, Zhao T, Zhu Z, et al. Metallothionein prevents cardiac pathological changes in diabetes by modulating nitration and inactivation of cardiac ATP synthase. J Nutr Biochem 2014; 25: 463-474.
94. Cong W, Ma W, Zhao T, et al. Metallothionein prevents diabetes-induced cardiac pathological changes, likely via the inhibition of succinyl-CoA:3-ketoacid coenzyme A transferase-1 nitration at Trp(374). Am J Physiol Endocrinol Metab 2013; 304: E826-E835.
95. Giacconi R, Bonfigli AR, Testa R, et al. +647 A/C and +1245 MT1A polymorphisms in the susceptibility of diabetes mellitus and cardiovascular complications. Mol Genet Metab 2008; 94: 98-104.
96. Yang L, Li H, Yu T, et al. Polymorphisms in metallothionein-1 and -2 genes associated with the risk of type 2 diabetes mellitus and its complications. Am J Physiol Endocrinol Metab 2008; 294: E987-E992.
97. Miao X, Sun W, Fu Y, et al. Zinc homeostasis in the metabolic syndrome and diabetes. Front Med 2013; 7: 31-52.
98. Li B, Tan Y, Sun W, et al. The role of zinc in the prevention of diabetic cardiomyopathy and nephropathy. Toxicol Mech Methods 2013; 23: 27-33.
99. Cho HY, Reddy SP, Kleeberger SR. Nrf2 defends the lung from oxidative stress. Antioxid Redox Signal 2006; 8: 76-87.
100. Li B, Liu S, Miao L, et al. Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy. Exp Diabetes Res 2012; 2012: 216512.
101. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 2004; 10: 549-557.
102. de Haan JB. Nrf2 activators as attractive therapeutics for diabetic nephropathy. Diabetes 2011; 60: 2683-2684.
103. He X, Kan H, Cai L, et al. Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. J Mol Cell Cardiol 2009; 46: 47-58.
104. Ramprasath T, Selvam GS. Potential impact of genetic variants in Nrf2 regulated antioxidant genes and risk prediction of diabetes and associated cardiac complications. Curr Med Chem 2013; 20: 4680-4693.
105. Chartoumpekis DV, Kensler TW. New player on an old field; the keap1/Nrf2 pathway as a target for treatment of type 2 diabetes and metabolic syndrome. Curr Diabetes Rev 2013; 9: 137-145.
106. Tan Y, Ichikawa T, Li J, et al. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 2011; 60: 625-633.
107. Bai Y, Cui W, Xin Y, et al. Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J Mol Cell Cardiol 2013; 57: 82-95.
108. Luo ZF, Qi W, Feng B, et al. Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome. Life Sci 2011; 88: 512-520.
109. Cui W, Li B, Bai Y, et al. Potential role for Nrf2 activation in the therapeutic effect of MG132 on diabetic nephropathy in OVE26 diabetic mice. Am J Physiol Endocrinol Metab 2013; 304: E87-E99.
110. Wang Y, Sun W, Du B, et al. Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-kappaB. Am J Physiol Heart Circ Physiol 2013; 304: H567-H578.
111. Fahey JW, Talalay P. Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem Toxicol 1999; 37: 973-979.
112. Tsai CY, Wang CC, Lai TY, et al. Antioxidant effects of diallyl trisulfide on high glucose-induced apoptosis are mediated by the PI3K/Akt-dependent activation of Nrf2 in cardiomyocytes. Int J Cardiol 2013; 168: 1286-1297.